Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Mascha Binder(Universität Hamburg), Gertraud Stocker(University Hospital Leipzig), Armin Jarosch(Charité - Universitätsmedizin Berlin), Daniel Pink(Universitätsmedizin Greifswald), Anica Högner(Charité - Universitätsmedizin Berlin), Peter Reichardt(Helios Hospital Berlin-Buch), Prisca Bartels(Charité - Universitätsmedizin Berlin), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Axel Hinke, Alexander Stein(Universität Hamburg), M. Stahl(Kliniken Essen-Mitte), Albrecht Kretzschmar(Roche (Switzerland)), Eray Goekkurt(Sorbonne Université), Frank Kullmann(Klinikum Weiden), Lisa Paschold
Journal of Clinical Oncology
June 1, 2023
10.1200/jco.2023.41.16_suppl.4032
Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k